HKSE - Delayed Quote HKD

Hansoh Pharmaceutical Group Company Limited (3692.HK)

Compare
16.700
+0.060
+(0.36%)
At close: 4:08:28 PM GMT+8
Currency in HKD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
12,098,090.000
10,103,806.000
9,382,410.000
9,935,141.000
8,690,234.000
Cost of Revenue
1,074,626.000
1,030,863.000
867,010.000
870,042.000
801,561.000
Gross Profit
11,023,464.000
9,072,943.000
8,515,400.000
9,065,099.000
7,888,673.000
Operating Expense
6,591,703.000
6,233,622.000
5,723,917.000
6,030,200.000
5,058,583.000
Operating Income
4,431,761.000
2,839,321.000
2,791,483.000
3,034,899.000
2,830,090.000
Net Non Operating Interest Income Expense
865,914.000
838,326.000
250,943.000
111,275.000
90,392.000
Pretax Income
5,384,458.000
3,766,155.000
2,948,428.000
3,300,082.000
3,098,299.000
Tax Provision
670,278.000
488,652.000
364,681.000
587,180.000
529,392.000
Net Income Common Stockholders
4,714,180.000
3,277,503.000
2,583,747.000
2,712,902.000
2,568,907.000
Average Dilution Earnings
-131,494.000
-131,759.000
--
-59,200.000
--
Diluted NI Available to Com Stockholders
4,582,686.000
3,145,744.000
2,583,747.000
2,653,702.000
2,568,907.000
Basic EPS
0.79
0.55
0.44
0.46
0.44
Diluted EPS
0.76
0.52
0.44
0.44
0.44
Basic Average Shares
5,925,920.504
5,924,899.050
5,915,822.196
5,921,040.161
5,876,243.659
Diluted Average Shares
6,021,192.162
6,019,650.142
5,929,483.310
5,997,857.724
5,878,078.730
Rent Expense Supplemental
--
5,457.000
8,651.000
--
--
Total Expenses
7,666,329.000
7,264,485.000
6,590,927.000
6,900,242.000
5,860,144.000
Net Income from Continuing & Discontinued Operation
4,714,180.000
3,277,503.000
2,583,747.000
2,712,902.000
2,568,907.000
Normalized Income
4,606,090.526
3,158,888.556
2,523,724.789
2,734,102.391
2,536,964.588
Interest Income
906,798.000
905,005.000
309,085.000
164,093.000
92,037.000
Interest Expense
40,884.000
66,679.000
58,142.000
52,818.000
1,645.000
Net Interest Income
865,914.000
838,326.000
250,943.000
111,275.000
90,392.000
EBIT
5,425,342.000
3,832,834.000
3,006,570.000
3,352,900.000
3,099,944.000
EBITDA
5,823,612.000
4,199,215.000
3,351,172.000
3,631,367.000
3,333,218.000
Reconciled Cost of Revenue
1,074,626.000
1,030,863.000
867,010.000
870,042.000
801,561.000
Reconciled Depreciation
398,270.000
366,381.000
344,602.000
278,467.000
233,274.000
Net Income from Continuing Operation Net Minority Interest
4,714,180.000
3,277,503.000
2,583,747.000
2,712,902.000
2,568,907.000
Total Unusual Items Excluding Goodwill
123,458.000
136,299.000
68,494.000
-25,789.000
38,525.000
Total Unusual Items
123,458.000
136,299.000
68,494.000
-25,789.000
38,525.000
Normalized EBITDA
5,700,154.000
4,062,916.000
3,282,678.000
3,657,156.000
3,294,693.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
15,368.526
17,684.556
8,471.789
-4,588.609
6,582.588
12/31/2020 - 6/14/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1558.HK HEC CJ PHARM
9.810
+0.41%
 
2096.HK Simcere Pharmaceutical Group Limited
6.560
-0.30%
 
1513.HK LIVZON PHARMA
25.600
-0.58%
 
2196.HK Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
13.300
-0.30%
 
IPN.PA Ipsen S.A.
120.00
+0.84%
 
0013.HK HUTCHMED
21.250
-9.77%
 
PROC Procaps Group S.A.
1.7500
-0.57%
 
INDV.L Indivior PLC
939.00
+2.85%
 
SUPN Supernus Pharmaceuticals, Inc.
37.56
-0.69%
 
RDY Dr. Reddy's Laboratories Limited
15.20
-0.39%